prexasertib
ACR-368 Small Molecule Target: CHK1, CHK2
Acrivon Therapeutics
Most recent annual filing: 2026-03-15
- ACR-6840 corporate update1H 2027ACR-6840 corporate update, 1H 2027, routine
- CDK11 program IND filing1H 2027CDK11 program IND filing, 1H 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
ACR-2316
Small Molecule Target: WEE1, PKMYT1
ACR-6840
Small Molecule Target: CDK11
ACR-368
Small Molecule Target: CHK1, CHK2
Technology platforms
AP3
Generative Phosphoproteomics Acrivon Predictive Precision Proteomics platform — quantifies compound-specific, drug-regulated pathway activity levels inside the intact cell via MS-based proteomic profiling and automated tumor imaging biomarker platform; applied to oncology drug discovery, patient selection (OncoSignature tests), indication finding, and resistance mechanism identification
Targets: CDK1, CDK2, PLK1, CHK1, CHK2, WEE1, PKMYT1, CDK11
Biotech Distilled coverage (13)
- 2026-08-13 UPDATE: Acrivon (ACRV) - The Phase 3 Now Has a Date, and the Runway Reaches It 🔒 Paid
- 2026-08-06 UPDATE: Acrivon (ACRV) - The Dosing Problem That Crashed the Stock Just Got Solved 🔒 Paid
- 2026-05-13 UPDATE: Acrivon (ACRV) - The 2H 2026 Catalyst Just Got Locked In 🔒 Paid
- 2026-04-27 UPDATE: Acrivon (ACRV) - RA Capital Just Backstopped the ATM at $1.80 🔒 Paid
- 2026-03-21 UPDATE: Acrivon (ACRV) - The Partnership Pitch Takes Shape Ahead of AACR 🔒 Paid
- 2026-03-07 UPDATE: Acrivon (ACRV) - Officially Cuts the Cord with its Diagnostic Vendor 🔒 Paid
- 2026-02-28 UPDATE: Acrivon (ACRV) - The Late-Breaking Letdown and the Anatomy of a Friday Flush. 🔒 Paid
- 2026-02-21 UPDATE: Acrivon (ACRV) Brings Its Moat In-House. 🔒 Paid
- 2026-01-25 Update: Acrivon (ACRV) - Catalyst Added: ACRV Takes the Main Stage in Europe. 🔒 Paid
- 2026-01-17 Insider Alert: Acrivon (ACRV) - Executives Are Eating Their Own Cooking.
- 2026-01-10 UPDATE: Acrivon (ACRV) Granular Review: Did the Market Just Throw the Baby Out with the Bathwater? 🔒 Paid
- 2026-01-08 ACRV UPDATE: Platform Supported. Acrivon (ACRV) Clears the Bar.
- 2026-01-05 Acrivon Therapeutics (ACRV): Scientific Deep Dive for ACR-2316 and ACR-368 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.